Taking PI3Kδ and PI3Kγ one step ahead: Dual active PI3Kδ/γ inhibitors for the treatment of immune-mediated inflammatory diseases

Current Topics in Microbiology and Immunology

Volumn 346, Issue 1, 2010, Pages 279-299

  Rommel, Christian ^a  

^a Intellikine Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; GLUCOCORTICOID; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE DELTA INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME INHIBITION; HUMAN; IMMUNE MEDIATED INFLAMMATORY DISEASE; IMMUNOCOMPETENT CELL; INFLAMMATORY DISEASE; LEUKOCYTE; LYMPHOCYTE; MAST CELL; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; ARTHRITIS; CELL MOTION; DRUG ANTAGONISM; INFLAMMATION; PHYSIOLOGY; REVIEW;

ARTHRITIS; CELL MOVEMENT; HUMANS; INFLAMMATION; KILLER CELLS, NATURAL; LYMPHOCYTES; MAST CELLS; NEUTROPHILS; PHOSPHATIDYLINOSITOL 3-KINASES; PNEUMONIA;

EID: 79952109496     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/82-2010-79     Document Type: Article

References (70)

1. Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, Tkaczyk C, Kuehn N, Gray A, Giddings J, Peskett E, Fox R, Bruce I, Walker C, Sawyer C, Okkenhaug K, Finan P, Vanhaesebroeck B (2004) Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 431(7011):1007-1011 (Pubitemid 39434424)
2. Ali K, Camps M, Pearce WP, Ji H, Rückle T, Kuehn N, Pasquali C, Chabert C, Rommel C, Vanhaesebroeck B (2008) Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. J Immunol 180 (4):2538-2544
3. Andrews S, Stephens LR, Hawkins PT (2007) PI3K class IB pathway in neutrophils. Sci STKE 2007(407):cm3
4. Arcaro A, Wymann MP (1993) Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor. Biochem J 296:297-301
5. Barbi J, Cummings HE, Lu B, Oghumu S, Rückle T, Rommel C, Lafuse W, Whitacre CC (2008) p110g facilitating an efficient induction of CXCR3 on activated T cells. Satoskar AR Blood 112(8):3048-3051
6. Bilancio A, Okkenhaug K, Camps M, Emery JL, Ruckle T, Rommel C, Vanhaesebroeck B (2006) Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood 107(2):642-650 (Pubitemid 43076389)
7. Camps M, Rückle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Françon B, Martin T, Gretener D, Perrin D, Leroy D, Vitte PA, Hirsch E, Wymann MP, Cirillo R, Schwarz MK, Rommel C (2005) Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 11(9):936-943 (Pubitemid 41294438)
8. Chang JD, Sukhova GK, Libby P, Schvartz E, Lichtenstein AH, Field SJ, Kennedy C, Madhavarapu S, Luo J, Wu D, Cantley LC (2007) Deletion of the phosphoinositide 3-kinase p110gamma gene attenuatesmurine atherosclerosis. ProcNatl Acad Sci USA 104(19):8077-8082 (Pubitemid 47185878)
9. Condliffe AM, Davidson K, Anderson KE, Ellson CD, Crabbe T, Okkenhaug K, Vanhaesebroeck B, Turner M, Webb L, Wymann MP, Hirsch E, Ruckle T, Camps M, Rommel C, Jackson SP, Chilvers ER, Stephens LR, Hawkins PT (2005) Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106(4):1432-1440 (Pubitemid 41129612)
10. Cosemans JM, Munnix IC, Wetzker R, Heller R, Jackson SP, Heemskerk JW (2006) Continuous signaling via PI3K isoforms b and g is required for platelet ADP receptor function in dynamic thrombus stabilization. Blood 108(9):3045-3052
11. Del Prete A, VermiW, Dander E, Otero K, Barberis L, LuiniW, Bernasconi S, SironiM, Santoro A, Garlanda C, Facchetti F, Wymann MP, Vecchi A, Hirsch E, Mantovani A, Sozzani S (2004) Defective dendritic cell migration and activation of adaptive immunity in PI3Kgammadeficient mice. EMBO J 23(17):3505-3515 (Pubitemid 39265540)
12. Doukas J, Eide L, Stebbins K, Racanelli-Layton A, Dellamary L, Martin M, Dneprovskaia E, Noronha G, Soll R, Wrasidlo W, Acevedo LM, Cheresh DA (2009) Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2, 4-diamino-6-(3-hydroxyphenyl)-pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther 328(3):758-765
13. Duan W (2005) Aguinaldo Datiles AM, Leung BP, Vlahos CJ, Wong WS. An anti-inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model. Int Immunopharmacol 5(3):495-502 (Pubitemid 40430757)
14. Durand CA, Hartvigsen K, Fogelstrand L, Kim S, Iritani S, Vanhaesebroeck B, Witztum JL, Puri KD, Gold MR (2009) Phosphoinositide 3-kinase p110delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol 183 (9):5673-5684
15. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8):550-562
16. Ferguson GJ, Milne L, Kulkarni S, Sasaki T, Walker S, Andrews S, Crabbe T, Finan P, Jones G, Jackson S, Camps M, Rommel C, Wymann M, Hirsch E, Hawkins P, Stephens L (2007) PI(3) Kgamma has an important context-dependent role in neutrophil chemokinesis. Nat Cell Biol 9 (1):86-91 (Pubitemid 46024201)
17. Firestein GS (2009) Rheumatoid arthritis in a mouse? Nat Clin Pract Rheumatol 5(1):1
18. Fougerat A, Gayral S, Gourdy P, Schambourg A, Rückle T, Schwarz MK, Rommel C, Hirsch E, Arnal JF, Salles JP, Perret B, Breton-Douillon M, Wymann MP, Laffargue M (2008) Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes. Circulation 117(10):1310-1317 (Pubitemid 351365672)
19. Fruman DA, Bismuth G (2009) Fine tuning the immune response with PI3K. Immunol Rev 228(1): 253-272
20. Giese N CAL101 ref (Barcelona. ASH) Hirsch E, Katanaev VL, Garlanda C, Azzolino O, Pirola L, Silengo L, Sozzani S, Mantovani A, Altruda F, Wymann MP (2000) Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 287(5455):1049-1053
21. Hirsch E, Braccini L, Ciraolo E, Morello F, Perino A (2009) Twice upon a time: PI3K's secret double life exposed. Trends Biochem Sci 34(5):244-248
22. Hooft van Huijsduijnen R, Rommel C (2006) Decompartmentalizing target validation-thinking outside the pipeline boxes. J Mol Med 84(10):802-813 (Pubitemid 44478864)
23. Ito K, Caramori G, Adcock IM (2007) Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. J Pharmacol Exp Ther 321(1):1-8 (Pubitemid 46456952)
24. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH (2005) PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 11(5):507-514 (Pubitemid 40685973)
25. Jarmin SJ, David R, Ma L, Chai JG, Dewchand H, Takesono A, Ridley AJ, Okkenhaug K, Marelli-Berg FM (2008) T cell receptor-induced phosphoinositide-3- kinase p110delta activity is required for T cell localization to antigenic tissue in mice. J Clin Invest 118(3): 1154-1164 (Pubitemid 351364622)
26. Ji H, Rintelen F, Waltzinger C (2007) Bertschy Meier D, Bilancio A, Pearce W, Hirsch E, Wymann MP, Rückle T, Camps M, Vanhaesebroeck B, Okkenhaug K, Rommel C. Inactivation of PI3Kgamma and PI3Kdelta distorts T-cell development and causes multiple organ inflammation. Blood 110(8):2940-2947 (Pubitemid 350006947)
27. Johnson Z, Power CA, Weiss C, Rintelen F, Ji H, Ruckle T, Camps M, Wells TN, Schwarz MK, Proudfoot AE, Rommel C (2004) Chemokine inhibition-why, when, where, which and how? Biochem Soc Trans 32(Pt 2):366-377
28. Kim MS, Rådinger M, Gilfillan AM (2008) The multiple roles of phosphoinositide 3-kinase in mast cell biology. Trends Immunol 29(10):493-501
29. Knight ZA, Shokat KM (2007a) Chemically targeting the PI3K family. Biochem Soc Trans 35 (pt 2):245-249 (Pubitemid 46596480)
30. Knight ZA, Shokat KM (2007b) Chemical genetics: where genetics and pharmacology meet. Cell 128(3):425-430 (Pubitemid 46198904)
31. Kok K, Geering B, Vanhaesebroeck B (2009) Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci 34(3):115-127
32. Konrad S, Ali SR, Wiege K, Syed SN, Engling L, Piekorz RP, Hirsch E, Nürnberg B, Schmidt RE, Gessner JE (2008) Phosphoinositide 3-kinases gamma and delta, linkers of coordinate C5a receptor-Fcgamma receptor activation and immune complex-induced inflammation. J Biol Chem 283(48):33296-33303
33. Laffargue M, Calvez R, Finan P, Trifilieff A, Barbier M, Altruda F, Hirsch E, Wymann MP (2002) Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function. Immunity 16(3):441-451 (Pubitemid 34260921)
34. Lee KS, Lee HK, Hayflick JS, Lee YC, Puri KD (2006) Inhibition of phosphoinositide 3-kinase delta attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J 20(3):455-465 (Pubitemid 44933322)
35. Li Z, Jiang H, Xie W, Zhang Z, Smrcka AV, Wu D (2000) Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science 287(5455): 1046-1049 (Pubitemid 30094361)
36. Lim DH, Cho JY, Song DJ, Lee SY, Miller M, Broide DH (2009) PI3K gamma-deficient mice have reduced levels of allergen-induced eosinophilic inflammation and airway remodeling. Am J Physiol Lung Cell Mol Physiol 296(2):L210-L219
37. Liu L, Puri KD, Penninger JM, Kubes P (2007) Leukocyte PI3Kgamma and PI3Kdelta have temporally distinct roles for leukocyte recruitment in vivo. Blood 110(4):1191-1198 (Pubitemid 47281416)
38. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8(8):627-644
39. Mackay CR (2008) Moving targets: cell migration inhibitors as new anti-inflammatory therapies. Nat Immunol 9(9):988-998
40. Martin AL, Schwartz MD, Jameson SC, Shimizu Y (2008) Selective regulation of CD8 effector T cell migration by the p110 gamma isoform of phosphatidylinositol 3-kinase. J Immunol 180(4):2081-2088
41. Marwick JA, Caramori G, Stevenson CS, Casolari P, Jazrawi E, Barnes PJ, Ito K, Adcock IM, Kirkham PA, Papi A (2009) Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice. Am J Respir Crit Care Med 179(7):542-548
42. Maus UA, Backi M, Winter C, Srivastava M, Schwarz MK, Rückle T, Paton JC, Briles D, Mack M, Welte T, Maus R, Bohle RM, Seeger W, Rommel C, Hirsch E, Lohmeyer J, Preissner KT (2007) Importance of phosphoinositide 3-kinase gamma in the host defense against pneumococcal infection. Am J Respir Crit Care Med 175(9):958-966 (Pubitemid 46684707)
43. Nashed BF, Zhang T, Al-Alwan M, Srinivasan G, Halayko AJ, Okkenhaug K, Vanhaesebroeck B, Hayglass KT, Marshall AJ (2007) Role of the phosphoinositide 3-kinase p110delta in generation of type 2 cytokine responses and allergic airway inflammation. Eur J Immunol 37(2): 416-424 (Pubitemid 46915581)
44. Okkenhaug K, Vanhaesebroeck B (2003) PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 3(4):317-330 (Pubitemid 37328684)
45. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, Pearce W, Meek SE, Salpekar A, Waterfield MD, Smith AJ, Vanhaesebroeck B (2002) Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297(5583):1031-1034 (Pubitemid 34856039)
46. Okkenhaug K, Ali K, Vanhaesebroeck B (2007) Antigen receptor signalling: a distinctive role for the p110delta isoform of PI3K. Trends Immunol 28(2):80-87 (Pubitemid 46176736)
47. Omori SA, Rickert RC (2007) Phosphatidylinositol 3-kinase (PI3K) signaling and regulation of the antibody response. Cell Cycle 6(4):397-402 (Pubitemid 46393440)
48. Pinho V (2007) de Castro Russo R, Amaral FA, de Sousa LP, Barsante MM, de Souza DG, Alves-Filho JC, Cara DC, Hayflick JS, Rommel C, Ruckle T, Rossi AG, Teixeira MM. Tissueand stimulus-dependent role of phosphatidylinositol 3-kinase isoforms for neutrophil recruitment induced by chemoattractants in vivo. J Immunol 179(11):7891-7898
49. Pinho V, Souza DG, Barsante MM, Hamer FP, De Freitas MS, Rossi AG, Teixeira MM (2005) Phosphoinositide-3 kinases critically regulate the recruitment and survival of eosinophils in vivo: importance for the resolution of allergic inflammation. J Leukoc Biol 77(5): 800-810 (Pubitemid 40628760)
50. Puri KD, Doggett TA, Douangpanya J, Hou Y, Tino WT, Wilson T, Graf T, Clayton E, Turner M, Hayflick JS, Diacovo TG (2004) Mechanisms and implications of phosphoinositide 3-kinase delta in promoting neutrophil trafficking into inflamed tissue. Blood 103(9):3448-3456 (Pubitemid 38525677)
51. Puri KD, Doggett TA, Huang CY, Douangpanya J, Hayflick JS, Turner M, Penninger J, Diacovo TG (2005) The role of endothelial PI3Kgamma activity in neutrophil trafficking. Blood 106 (1):150-157 (Pubitemid 40967187)
52. Randis TM, Puri KD, Zhou H, Diacovo TG (2008) Role of PI3Kdelta and PI3Kgamma in inflammatory arthritis and tissue localization of neutrophils. Eur J Immunol 38(5):1215-1224
53. Reif K, Okkenhaug K, Sasaki T, Penninger JM, Vanhaesebroeck B, Cyster JG (2004) Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. J Immunol 173(4):2236
54. Rommel C, Camps M, Ji H (2007) PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 7(3):191-201
55. Rückle T, Schwarz MK, Rommel C (2006) PI3Kgamma inhibition: towards an 'aspirin of the 21st century'? Nat Rev Drug Discov 5(11):903-918
56. Sadhu C, Masinovsky B, Dick K, Sowell CG, Staunton DE (2003) Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J Immunol 170(5):2647-2654 (Pubitemid 36245657)
57. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, Bolon B, Wakeham A, Itie A, Bouchard D, Kozieradzki I, Joza N, Mak TW, Ohashi PS, Suzuki A, Penninger JM (2000) Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 287(5455):1040-1046
58. Saudemont A, Garçon F, Yadi H, Roche-Molina M, Kim N, Segonds-Pichon A, Martín-Fontecha A, Okkenhaug K, Colucci F (2009) p110gamma and p110delta isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease. Proc Natl Acad Sci USA 106(14):5795-5800
59. Sinclair LV, Finlay D, Feijoo C, Cornish GH, Gray A, Ager A, Okkenhaug K, Hagenbeek TJ, Spits H, Cantrell DA (2008) Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol 9(5):513-521 (Pubitemid 351560520)
60. Swat W, Montgrain V, Doggett TA, Douangpanya J, Puri K, Vermi W, Diacovo TG (2006) Essential role of PI3Kdelta and PI3Kgamma in thymocyte survival. Blood 107(6):2415-2422 (Pubitemid 43345562)
61. Takeda M, Ito W, Tanabe M, Ueki S, Kato H, Kihara J, Tanigai T, Chiba T, Yamaguchi K, Kayaba H, Imai Y, Okuyama K, Ohno I, Sasaki T, Chihara J (2009) Allergic airway hyperresponsiveness, inflammation, and remodeling do not develop in phosphoinositide 3-kinase gammadeficient mice. T J Allergy Clin Immunol 123(4):805-812
62. Tassi I, Cella M, Gilfillan S, Turnbull I, Diacovo TG, Penninger JM, Colonna M (2007) p110gamma and p110delta phosphoinositide 3-kinase signaling pathways synergize to control development and functions of murine NK cells. Immunity 27(2):214-227 (Pubitemid 47284932)
63. Thomas MJ, Smith A, Head DH, Milne L, Nicholls A, Pearce W, Vanhaesebroeck B, Wymann MP, Hirsch E, Trifilieff A, Walker C, Finan P, Westwick J (2005) Airway inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases. Eur J Immunol 35(4):1283-1291 (Pubitemid 40542236)
64. Thomas M, Edwards MJ, Sawicka E, Duggan N, Hirsch E, Wymann MP, Owen C, Trifilieff A, Walker C, Westwick J, Finan P (2009) Essential role of phosphoinositide 3-kinase gamma in eosinophil chemotaxis within acute pulmonary inflammation. Immunology 126(3):413-422
65. Vanhaesebroeck B, Rohn JL, Waterfield MD (2004) Gene targeting: attention to detail. Cell 118 (3):274-276 (Pubitemid 39061107)
66. Vlahos CJ et al (1994) A specific inhibitor of phosphatidylinositol 3 kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269(7):5241-5248
67. Walker EH, Pacold E, Perisic O, Stephens L, Hawkins PT, Wymann MP, Williams RL (2000) Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and Staurosporine. Mol Cell 6:909-919
68. Webb LM, Vigorito E, Wymann MP, Hirsch E, TurnerM(2005) Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase. J Immunol 175(5):2783-2787 (Pubitemid 41170493)
69. Wymann MP, Björklö f K, Calvez R, Finan P, Thomast M, Trifilieff A, Barbier M, Altruda F, Hirsch E, Laffargue M (2003) Phosphoinositide 3-kinase gamma: a key modulator in inflammation and allergy. Biochem Soc Trans 31(Pt 1):275-280 (Pubitemid 36241444)
70. Zhang TT, Okkenhaug K, Nashed BF, Puri KD, Knight ZA, Shokat KM, Vanhaesebroeck B, Marshall AJ (2008) Genetic or pharmaceutical blockade of p110delta phosphoinositide 3-kinase enhances IgE production. J Allergy Clin Immunol 122(4):811-81